Bolsas y Mercados Españoles
Company
search
GRIFOLS, S.A.
AddressCL JESUS Y MARIA 6, 08022 BARCELONA 
Listed Capital119,603,705.00 Euros



GRIFOLS CLASE B
ISINES0171996095 TickerGRF.P Nominal0.05 MarketContinuous Market Admitted Capital13,071,255.50 Euros 

Last prices
DateHourCloseRef.% Dif.LastHighLowAvg.VolumeTurnover
09/12/202212:17:39- 7.35001.977.49507.51507.38507.455620,256151,019.94
08/12/2022Close7.35007.4850-1.807.35007.54007.31007.4219101,653754,461.77
X
09/12/2022 12:36:21
BidAsk
OrdersVolumePricePriceVolumeOrders
11137.48507.50006921
Data Delayed 15 minutes.

Last pay
TypeEx-datePayment DateConcept
Dividend03/06/202107/06/2021Final 2020

Last split
DateEquivalence
04/01/20162 x 1

Last reverse split
DateEquivalence
 

Last capital increase
PeriodProportionType
22/04/201368 x 10,000Premium


 2022
until 8/12
2021202020192018
Capitalisation *
(thousands of euros)
1,921,4752,643,0084,031,1755,437,6424,219,401
Shares
(x 1,000)
261,425261,425261,425261,425261,425
Period Close Price
(euros)
7.350010.110015.420020.800016.1400
Period Last Price
(euros)
7.350010.110015.420020.800016.1400
Period High Price
(euros)
12.570016.940023.650021.300021.3000
Period Low Price
(euros)
5.75009.020012.940015.600015.6400
Volume
(thousands of shares)
76,05355,71646,81547,33335,840
Turnover
(thousands of euros)
725,501747,476798,531867,545647,810

Profile

Grifols is a global company in the health sector that markets its products in more than 100 countries and has a direct presence in more than 30 countries. The company’s class A shares have been listed on the Spanish Stock Exchange (MCE:GRF) since 2006 and have been part of the Ibex-35 since 2008.  In 2011, the company listed non-voting class B shares on the Mercado Continuo (MCE:GRF.P) and in NASDAQ-United States via ADRs  (NASDAQ: GRFS).

Grifols has become one of the largest plasma companies and in recent years has built up a strong network of plasma donation centers in the United States, Europe, Egypt and Canada, which has enabled it to expand and diversify its access to plasma. With the plasma obtained, Grifols produces essential medicines to treat chronic, rare and sometimes very serious diseases. As a recognized leader in transfusion medicine, the company has a comprehensive portfolio of solutions designed to improve safety from donation to transfusion. In addition, it supplies biological products for non-therapeutic use.

Grifols has the necessary infrastructure and experience in planning future needs to maintain a path of sustainable growth based on continuous improvement and the optimization of processes and costs. Its solid manufacturing presence, mainly in the United States and Spain, has enabled to promote a scaled global dimension with a distinctly global dimension, as well as to the growing market demand. 

You can find more information about Grifols on www.grifols.com

Source: Issuing company.
09/12/2022 00:01:02

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties for a fee, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.

Follow us in:
Copyright © BME 2022